🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD+ Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase

Cancers(2022)10.3390/cancers14153572Source: DataRank Database

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD+ Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 1.58)OA: goldTopics (35)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Christopher A. Koczor ORCID,Kate M. Saville ORCID,Faisal Hayat ORCID,Alison Beiser ORCID,Steven McClellan ORCID

Live enrichment

PubMed:35892832 OpenAlex:https://openalex.org/W4286587327

National Institutes of Health (NIH)

Grant: ES029518

National Institutes of Health (NIH)

Grant: CA148629

National Institutes of Health (NIH)

Grant: ES014811

National Institutes of Health (NIH)

Grant: ES028949

National Institutes of Health (NIH)

Grant: CA238061

National Institutes of Health (NIH)

Grant: CA236911

National Institutes of Health (NIH)

Grant: AG069740

National Institutes of Health (NIH)

Grant: ES032522

National Institutes of Health (NIH)

Grant: NSF-1841811

National Institutes of Health

Grant: 1R01CA236911-01A1

SON-mediated RNA splicing in glioblastoma

National Institutes of Health

Grant: 5P01ES028949-04

Greater Caribbean Center for Ciguatera Research

National Institutes of Health

Grant: 1R01CA238061-01

Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparities

National Institutes of Health

Grant: 5R01AG069740-02

The Paternal Age Effect - Enhanced Germ Cell Mutagenesis Modulated by the TRP53/APE1/MDM2 Tumor Suppressor Axis

National Science Foundation

Grant: 1841811

Greater Caribbean Center for Ciguatera Research

National Institutes of Health

Grant: 5U01ES029518-04

Measuring genomic DNA damage and DNA repair capacity in longitudinal population samples - a step towards precision prevention

National Institutes of Health

Grant: 5R01CA148629-05

Novel approaches to enhance tumor cell cytotoxicity of alkylating agents

National Institutes of Health

Grant: 5R01ES014811-08

A Systems Approach to Mapping the DNA Damage Response

FWCI

1.58

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/14/15/3572/pdf?version=1658488091

publisherhttps://www.mdpi.com/2072-6694/14/15/3572/pdf?version=1658488091

publisherhttps://www.mdpi.com/2072-6694/14/15/3572/pdf

journalhttps://doi.org/10.3390/cancers14153572

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35892832

Fields of Study

PARP inhibition in cancer therapyGlioma Diagnosis and TreatmentDNA Repair Mechanisms0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicine

Keywords

TemozolomideNAD+ kinaseCancer researchDNA repairDNA damagePARP1O-6-methylguanine-DNA methyltransferaseSynthetic lethalityPoly ADP ribose polymeraseCytotoxicityChemistryPharmacologyBiologyMethyltransferaseGlioblastomaDNABiochemistryEnzymeIn vitroBERTMZ resistanceNAD<sup>+</sup>MSH6MMRArticlePARP activationMGMTPARG inhibition

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being